KLRK1 and neoplasm: Unlike conventional CAR designs targeting specific tumor-associated antigens, NKG2D CARs have the ability to recognize a broader array of ligands, providing a unique opportunity to eliminate the heterogeneous populations of senescent cells that accumulate in aging tissues and pathological conditions.